Xanadu and the University of Alberta have started a research partnership focused on photodynamic cancer therapy. Their project will develop quantum algorithms for modeling photosensitizers, molecules activated by light to damage localized tumor cells.
Quantum Computing Report reported the partnership on August 13, 2026. The announcement describes planned algorithm research, not a discovered drug or completed quantum experiment.
Why photosensitizers are difficult to model
Photodynamic therapy combines a drug, light at a selected wavelength, and oxygen. Light activates the photosensitizer. The activated molecule then produces reactive oxygen species near targeted tissue.
Researchers need to predict absorption spectra, excited-state dynamics, energy transfer, and singlet-oxygen production. These processes involve changing electronic states and interactions between light and matter. Standard density functional theory often relies on approximations for such behavior.
The Xanadu and Alberta team plans to study quantum methods for those calculations. Professor Alex Brown, chair of chemistry at the University of Alberta, leads the university side.
What the project will build
The partnership names three technical goals:
- Algorithms for excited-state and light-matter simulations
- Methods for optimizing photosensitizer properties
- New photodynamic modeling tools inside PennyLane
PennyLane is Xanadu's open-source software framework for quantum machine learning, chemistry, and hybrid workflows. Adding photodynamic models would give researchers a common development route before fault-tolerant photonic hardware reaches the required scale.
No patient or drug result exists yet
The announcement contains no named drug candidate, processor run, classical benchmark, or experimental treatment result. Researchers are starting with algorithm development and computational benchmarking.
Fault-tolerant chemistry workloads also need logical qubits beyond current commercial photonic systems. Our quantum drug discovery overview places commercially relevant molecule simulation years beyond today's noisy hardware.
The partnership still targets a useful gap. Most quantum chemistry work studies ground-state energies. Photodynamic therapy depends heavily on excited states and light-driven transitions, giving the project a more specific technical goal than a broad drug-discovery announcement.
What would count as progress
A first useful result would define one photosensitizer problem, compare quantum resource estimates against leading classical methods, and publish reproducible code. A later hardware run should report error rates and solution quality next to a classical baseline.
Until then, this project represents research intent. Xanadu and the University of Alberta have named a hard chemistry problem and a software path. Evidence starts with published algorithms and benchmarks.